Trial Profile
A phase Ib trial to investigate Intralesional CAVATAK and KEYTRUDA in advanced head and neck cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Gebasaxturev (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Acronyms ITCAHN study
- 29 Mar 2018 According to an Immutep Limited media release, this trial is planned to start in 2018.
- 23 Nov 2017 New trial record